Receiving an official letter signed by a health agency has raised concerns among many individuals. Recently, thousands of such letters were sent to mailboxes, but they do not concern a drug recall, a stock shortage, or a major sanitary scandal. Instead, they address a less obvious topic: the potential link between certain hormonal contraceptives and a rare risk of meningioma, a type of brain tumor. This has sparked legitimate questions and a mix of concern and confusion among affected women. A study by EPI-PHARE found a very slight increase in the risk of meningioma among women using a contraceptive containing desogestrel for at least one year. This led the ANSM, France's national drug safety agency, to send personalized information letters to affected users and healthcare professionals. Receiving this letter does not indicate illness or an emergency, and it is emphasized that individuals should not stop their contraception on their own initiative, as this could lead to an unwanted pregnancy. The ANSM recommends discussing the matter with a doctor or midwife to assess individual situations, without recommending a systematic MRI for all users. The letters were prompted by a study conducted by EPI-PHARE, which highlighted a very slight increase in the risk of meningioma among women using a contraceptive based on desogestrel for an extended period. This information was serious enough for the European Medicines Agency to request the addition of this note in the leaflets of affected contraceptives in July 2026. In September 2026, the ANSM decided to go beyond a simple update and directly inform women using this type of pill and healthcare professionals who prescribed it. This approach of transparency explains the solemn tone of the received documents. The ANSM clearly states that receiving the letter does not mean being sick. It is neither a diagnosis nor a medical emergency. It is a preventive and informative approach intended to ensure that each affected woman has the same information as her doctor. The ANSM emphasizes that individuals must not stop their contraception on their own initiative after reading the letter. A sudden stop, taken in a moment of panic, could expose individuals to a more immediate and concrete risk, that of an unwanted pregnancy. This kind of reflex, understandable in the face of a word like meningioma, should be tempered by a bit of distance. The recommended approach is dialogue, not alarm. Upon receiving the letter, individuals are advised to engage in a discussion with their doctor or midwife to assess their individual situation, without haste or systematic examination. It is important to note that the ANSM does not recommend a systematic MRI for all users of desogestrel. It is not a question of rushing to an imaging examination as soon as the letter is read, but rather of opening a discussion adapted to each individual's circumstances. This approach fits into a broader policy of monitoring progestogens carried out by the ANSM, which has multiplied this type of information actions for several years. The stated objective remains the same: to allow each individual to remain an active participant in their health, rather than seeking answers on their own on the internet, which are often anxiety-inducing and rarely adapted to one's personal situation. In the end, this letter resembles less an alarm than an invitation to shared vigilance. The risk mentioned remains rare, contraception remains an essential tool, and the best compass remains, as often, a conversation with a trusted healthcare professional. One question remains simple, but far from trivial: and if this transparency, however destabilizing it may be at first, became the new norm for all daily medications?